Clinical and laboratory features of African-Brazilian patients with systemic sclerosis.
African-Brazilians
Autoantibodies
Diffuse scleroderma
Ethnicity
Limited scleroderma
Systemic sclerosis
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
05
01
2019
accepted:
22
04
2019
revised:
15
04
2019
pubmed:
9
5
2019
medline:
11
11
2020
entrez:
9
5
2019
Statut:
ppublish
Résumé
African-Brazilians comprise a group of blacks and "pardos." As racial differences can be associated with distinct presentations, we evaluated the clinical and serological associations of African-Brazilians with systemic sclerosis (SSc). Sera from 260 adult SSc patients (203 whites and 57 African-Brazilians) were evaluated. Patients with overlap syndromes were excluded. Clinical and demographic data were obtained from an electronic register database. Laboratory analysis included the following: anti-CENP-A/CENP-B, Scl70, RNA polymerase III, Ku, fibrillarin, Th/To, PM-Scl75, and PM-Scl100 by line immunoassay and anti-nuclear antibodies (ANA) by indirect immunofluorescence (IIF) on HEp-2 cells. African-Brazilian SSc patients presented shorter disease duration (12.8 ± 6.5 vs. 15.9 ± 8.1 years, p = 0.009), higher frequency of nucleolar ANA pattern (28% vs. 13%, p = 0.008), and lower frequencies of centromeric ANA pattern (14% vs. 29%, p = 0.026) and CENP-B (18% vs. 34%, p = 0.017), as well as an association with severe interstitial lung disease (58% vs. 43%; p = 0.044). Further comparison of ethnic groups according to subsets revealed that diffuse SSc African-Brazilian patients presented higher frequency of pulmonary hypertension (p = 0.017), heart involvement (p = 0.037), nucleolar ANA pattern (p = 0.036), anti-fibrillarin antibodies (p = 0.037), and higher mortality (48% vs. 19%; p = 0.009). A different pattern was observed for the limited subset with solely a lower frequency of esophageal involvement (p = 0.050) and centromeric ANA pattern (p = 0.049). Survival analysis showed that African-Brazilians had a higher mortality, when adjusted for age, gender, and clinical subset (RR 2.06, CI 95% 1.10-3.83, p = 0.023). African-Brazilians have distinct characteristics according to clinical subset and an overall more severe SSc than whites, similar to the blacks from other countries.Key Points • African-Brazilian SSc patients were associated with severe interstitial lung disease and nucleolar ANA pattern when compared to white SSc patients. • When disease subsets were considered, African-Brazilian patients with diffuse SSc presented association with pulmonary hypertension, heart involvement, nucleolar ANA pattern, and anti-fibrillarin antibodies. • White SSc patients were associated with centromeric ANA pattern. • Survival analysis at 5, 10, 15, and 20 years, adjusted for age, gender, and disease subset, was significantly worse in African-Brazilian SSc patients.
Identifiants
pubmed: 31065858
doi: 10.1007/s10067-019-04575-5
pii: 10.1007/s10067-019-04575-5
doi:
Substances chimiques
Antibodies, Antinuclear
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9-17Subventions
Organisme : Fundação de Amparo à pesquisa do Estado de São Paulo
ID : 2015/03756-4
Organisme : Conselho Nacional de Desenvolvimento Científico e Tecnológico
ID : 3053068/2014
Références
Medicine (Baltimore). 2013 Jul;92(4):191-205
pubmed: 23793108
J Rheumatol. 2011 Aug;38(8):1622-30
pubmed: 21572159
Medicine (Baltimore). 2014 Jul;93(5):177-85
pubmed: 25181310
Chest. 2007 Jan;131(1):217-22
pubmed: 17218579
Ann Rheum Dis. 2019 Jul;78(7):879-889
pubmed: 30862649
Nat Rev Genet. 2002 Aug;3(8):611-21
pubmed: 12154384
Autoimmun Rev. 2012 Dec;12(2):114-20
pubmed: 22776784
J Rheumatol. 1998 Jan;25(1):84-8
pubmed: 9458208
Arthritis Rheum. 2013 Nov;65(11):2737-47
pubmed: 24122180
Rheumatology (Oxford). 1999 May;38(5):397-400
pubmed: 10371275
Ann Rheum Dis. 2007 Jun;66(6):754-63
pubmed: 17234652
J Rheumatol. 2016 Oct;43(10):1816-1824
pubmed: 27481902
Br J Rheumatol. 1998 Jan;37(1):15-20
pubmed: 9487245
Arthritis Care Res (Hoboken). 2016 Nov;68(11):1736-1741
pubmed: 27014968
Arthritis Rheum. 2005 Aug;52(8):2425-32
pubmed: 16052583
Arthritis Rheum. 2007 Mar 15;57(2):318-26
pubmed: 17330281
Semin Arthritis Rheum. 2001 Apr;30(5):332-46
pubmed: 11303306
Medicine (Baltimore). 2017 Dec;96(51):e8980
pubmed: 29390428
Arthritis Rheum. 1997 Apr;40(4):734-42
pubmed: 9125258
J Rheumatol. 2007 Jan;34(1):104-9
pubmed: 17117486
J Rheumatol. 1988 Feb;15(2):202-5
pubmed: 3361530
Arthritis Rheumatol. 2015 Dec;67(12):3234-44
pubmed: 26246178
PLoS One. 2011 Feb 16;6(2):e17063
pubmed: 21359226
Arthritis Res Ther. 2003;5(2):80-93
pubmed: 12718748
Clin Rheumatol. 2009 Sep;28(9):1121-5
pubmed: 19437086
Rev Bras Reumatol Engl Ed. 2017 Mar - Apr;57(2):107-114
pubmed: 28343614
Rheumatol Int. 2018 Apr;38(4):657-662
pubmed: 29185086
Rev Bras Reumatol. 2011 Jul-Aug;51(4):314-8, 323-4
pubmed: 21779708
Curr Opin Rheumatol. 2012 Nov;24(6):642-8
pubmed: 22955018
Semin Arthritis Rheum. 2005 Aug;35(1):35-42
pubmed: 16084222
Arthritis Rheum. 2012 Sep;64(9):2986-94
pubmed: 22576620
Clin Rheumatol. 2011 Oct;30(10):1333-9
pubmed: 21523365
Arthritis Rheum. 1994 Jun;37(6):902-6
pubmed: 8003063
Nat Rev Rheumatol. 2010 Feb;6(2):112-6
pubmed: 20125179
Ann Rheum Dis. 2012 Aug;71(8):1355-60
pubmed: 22615460
Autoimmunity. 2011 Nov;44(7):576-84
pubmed: 21875377
Arthritis Rheum. 1989 Jan;32(1):54-60
pubmed: 2783552